SCHEMBL26075168

SCHEMBL26075168

CCOc1ccc(-c2ccc(-c3cc(C)c4cc(F)ccc4n3)cc2CC)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 2/20 0.46
▸ KDM4E B2RXH2 4/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ PLA2G2A P14555 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ DHODH Q02127 6/20 0.41
▸ GAA P10253 1/20 0.40
▸ FFAR1 O14842 2/20 0.39
▸ FFAR4 Q5NUL3 2/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ TP53 P04637 2/20 0.39
▸ USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075148 0.90 PDE10A (0.43) PDE10AKDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL26075172 0.90 MEN1 (0.44) PDE10AKDM4ESMN1; SMN2HPGDMEN1
SCHEMBL26075130 0.89 HMOX1 (0.43) PDE10AKDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL26075154 0.86 KDM4E (0.50) PDE10AKDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL26075298 0.85 HMOX1 (0.45) PDE10AKDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL26075988 0.85 PDE10A (0.45) PDE10AKDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL26075173 0.84 SCN9A (0.42) PDE10AKDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL26075139 0.82 PDE10A (0.42) PDE10AKDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL26075339 0.81 DHODH (0.39) PDE10APLA2G2ADHODH
SCHEMBL26075529 0.81 ESR1 (0.53) KDM4ESMN1; SMN2ALDH1A1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD PDE10A 3462/4885KDM4E 1396/4885SMN1; SMN2 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback